Sysmex Asia Pacific Pte Ltd. (Location: Singapore, President and CEO: Frank Buescher) announces that the Company has begun providing direct sales and support in India for Hematology Business. With more than 1.3 billion people, India is the world’s second most populous nation, after China, and the country’s real GDP continues to grow significantly. In addition […]

We are happy to announce the launch of the dedicated calibrators and controls for Edoxaban which are to be used with Biophen DiXal and Biophen Heparin (LRT). Biophen DiXal is a specific reagent for measuring direct factor Xa inhibitors while Biophen Heparin is an universal liquid reagent for indirect and direct factor Xa inhibitors. With […]

Sysmex Corporation responded to a call by the Japan International Cooperation Agency (JICA) for proposals under the second fiscal 2017 Collaboration Program with the Private Sector for Disseminating Japanese Technology for Social and Economic Development of Developing Countries. Sysmex’s proposal “Dissemination of Automated Urinalysis Diagnosis technology in the Republic of Ghana” was selected.

Sysmex Corporation announces its accreditation under the international standard ISO Guide 34 (General requirements for the competence of reference material producers). It is important for laboratories to ensure traceability, in order to ensure the quality of their test results. Laboratories ensure traceability through routine calibration and quality control. The standard materials used in this calibration […]

Sysmex Corporation offers a new network solution, Caresphere,™ to provide new value through the intelligent use of information by people involved in testing and healthcare, with a view to accelerating the future use of information in healthcare. Caresphere™ creates an environment for linking and analyzing a variety of information from testing instruments and laboratory information […]

Sysmex Corporation celebrated the 50th anniversary of its establishment on February 20, 2018. We offer our heartfelt appreciation for the support of our customers and all other stakeholders since the time of our establishment in 1968.

Colorectal cancer is the second most commonly occurring cancer in Malaysia (Malaysian National Cancer Registry Report 2007-2011). A new liquid biopsy testing to monitor the progression of metastatic cases of colorectal cancer has been developed by Sysmex Inostics in collaboration with Merck and is exclusively available in Pantai Premier Pathology, Malaysia.

The Dow Jones Sustainability Indexes are developed through collaboration between S&P Dow Jones Indices of the United States and Robeco SAM, a Swiss research specialist in the area of socially responsible investment. This year Sysmex has been selected for inclusion in the DJSI World for the second consecutive year.